Telitacicept在ACR 2025大会公布的中国3期临床试验突破性结果显示,相比安慰剂在原发性舍格伦综合征ESSDAI评分方面具有临床意义和统计学显著性改善。
Telitacicept在ACR 2025大会公布的中国3期临床试验突破性结果显示,相比安慰剂在原发性舍格伦综合征ESSDAI评分方面具有临床意义和统计学显著性改善。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.